Holen Sie sich die Stockscreener-App
152.50
2.10%
3.13
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$149.37
Offen:
$149.69
24-Stunden-Volumen:
8.51M
Relative Volume:
1.19
Marktkapitalisierung:
$189.20B
Einnahmen:
$29.05B
Nettoeinkommen (Verlust:
$8.11B
KGV:
23.62
EPS:
6.4563
Netto-Cashflow:
$9.16B
1W Leistung:
+7.43%
1M Leistung:
+25.66%
6M Leistung:
+38.28%
1J Leistung:
+55.55%
1-Tages-Spanne:
$148.71
$153.13
1-Wochen-Bereich:
$140.01
$153.13
52-Wochen-Spanne:
$93.37
$153.13
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
152.50 | 185.32B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,058.18 | 913.67B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
239.99 | 572.91B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
223.43 | 387.09B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
MRK
Merck Co Inc
|
121.93 | 297.22B | 65.00B | 18.26B | 13.05B | 7.2751 |
|
AZN
Astrazeneca Plc
|
193.03 | 290.15B | 58.07B | 9.40B | 9.87B | 3.0115 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Plato Investment Management Ltd Acquires 6,668 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Canada Post Corp Registered Pension Plan Has $11.64 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Assessing Gilead Sciences (GILD) Valuation After Its Strong Recent Share Price Performance - Yahoo Finance
Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O'day Sells 115,640 Shares - MarketBeat
Gilead Sciences CEO O’Day sells $17.3 million in stock - Investing.com
Gilead Sciences CEO O’Day sells $17.3 million in stock By Investing.com - Investing.com India
Biopharma bites: Dosing pause for uniQure's gene therapy, EU OK for GSK's Nucala, and a label update for Gilead's CAR-T - FirstWord Pharma
Gilead’s Dietmar Berger Reflects On Pipeline After First Year As CMO - Citeline News & Insights
Gilead is advertising around the Super Bowl to get out the word about new HIV-prevention drug - The Business Journals
Is Gilead Sciences (GILD) a 'Buy' Ahead of Its Upcoming Earnings Announcement? - Yahoo Finance
Gilead (GILD) Gains FDA Nod for Expanded Use of Yescarta in Lymp - GuruFocus
FDA Updates Yescarta Label, Boosts Gilead's (GILD) Market Positi - GuruFocus
Gilead wins favorable FDA label update for Yescarta (GILD) - Seeking Alpha
Gilead Sciences Says Yescarta Won FDA Label Update, Removing Use Limits for Relapsed CNS Lymphoma Patients - marketscreener.com
Gilead Sciences (GILD) Valuation Check After Oncology And HIV Therapy Momentum - simplywall.st
J.W. Cole Advisors Inc. Purchases 7,397 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Envestnet Asset Management Inc. Lowers Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Is Gilead Sciences (GILD) Still Attractive After Strong Multi‑Year Share Price Gains - Yahoo Finance
Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Yahoo Finance
Ashton Thomas Private Wealth LLC Acquires 10,107 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stock Holdings Increased by Jones Financial Companies Lllp - MarketBeat
Machina Capital S.A.S. Makes New $1.65 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
ABN AMRO Bank N.V. Acquires Shares of 46,091 Gilead Sciences, Inc. $GILD - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Sells 60,982 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by AGF Management Ltd. - MarketBeat
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
Gilead Sciences Stock Surged 50%, Here's Why - Trefis
This Overlooked Biotech Giant Could Surprise Investors This Quarter - Barchart.com
Here's Why Gilead Sciences Stock Surged 21% in a Month - Finviz
Gilead Sciences, Inc. (GILD): A bull case theory - MSN
Earnings Preview: Gilead Sciences (GILD) Q4 Earnings Expected to Decline - Yahoo Finance
Gilead Sciences (GILD) to Release Quarterly Earnings on Tuesday - MarketBeat
Principal Financial Group Inc. Trims Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Targeted Cancer Therapy Market to Reach US$ 175.48 Billion by 2035 Driven by Precision Oncology Adoption, ADC Innovation, and Regulatory Productivity Says Astute Analytica - GlobeNewswire Inc.
Gilead Sciences Oncology Push Gains Traction With Trodelvy Keytruda Results - Yahoo Finance
Gilead’s Growing Oncology Role Reshapes The Investment Case For GILD - simplywall.st
Gilead Sciences, Inc. (GILD): A Bull Case Theory - Finviz
Implied Volatility Surging for Gilead Sciences Stock Options - Nasdaq
Gilead Sciences (NASDAQ:GILD) Sets New 12-Month High on Analyst Upgrade - MarketBeat
Synopsys, Rocket Companies, On Holding And A Health Care Stock On CNBC's 'Final Trades' - Benzinga
Gilead Sciences, Inc. $GILD Position Cut by TD Waterhouse Canada Inc. - MarketBeat
Atlantic Union Bankshares Corp Has $19.61 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Truist Securities Raises Price Target on Gilead Sciences, Inc. (GILD) to $145, Keeps Buy Rating - Insider Monkey
Mediolanum International Funds Ltd Buys 9,971 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Thrivent Financial for Lutherans Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
AE Wealth Management LLC Buys 8,554 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Rose 4% This Week. Here’s Where the Stock Could Be Headed in 2026 - TIKR.com
UBS Turns More Bullish on Gilead Sciences, Inc. (GILD) Amid Positive Pharma Sector Outlook - Finviz
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $146.00 at Leerink Partners - MarketBeat
10,471 Shares in Gilead Sciences, Inc. $GILD Acquired by Winnow Wealth LLC - MarketBeat
National Pension Service Raises Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gilead Sciences Inc-Aktie (GILD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| O'Day Daniel Patrick | Chairman & CEO |
Feb 05 '26 |
Sale |
150.00 |
115,640 |
17,346,000 |
613,912 |
4.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):